Immune Checkpoint Inhibitors in Resectable and Locoregionally Advanced HNSCC: Past Lessons, Present Evidence, and Future Directions. (PubMed, Oncologist) - Sep 18, 2026 - "We provide an overview of ongoing studies exploring ICI-based approaches and combinations for neoadjuvant adaptive response, surgical strategies including surgical conversion and organ preservation, and radiotherapy optimization. Additionally, we review ongoing clinical trials evaluating ICIs in combination with chemotherapy, antibody-drug conjugates, targeted therapy, radiotherapy-including stereotactic body radiotherapy (SBRT), novel ICIs, and therapeutic cancer vaccines targeting HPV or tumor neoantigens."
Checkpoint inhibition • Journal • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
|
|
Bhumsuk Keam; Kaewta Jeerapradit; Nuttapong Ngamphaiboon
|